Wells Fargo analyst Derek Archila raised the firm’s price target on Septerna (SEPN) to $18 from $11 and keeps an Equal Weight rating on the shares. While the firm remains on the sidelines due to the earliness of Septerna’s wholly-owned programs, the recent Novo Nordisk (NVO) deal helps validate its platform and provides additional cash runway.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SEPN:
- Septerna, Inc.: Strategic Partnerships and Promising Pipeline Drive Buy Rating
- Septerna reports Q1 EPS (49c), consensus (45c)
- Novo Nordisk (NVO) Signs $2.2B Deal to Develop Weight-Loss Pills
- Septerna Enters Major Collaboration with Novo Nordisk
- Novo Nordisk, Septerna to collaborate to develop obesity pills